Genprex (NASDAQ:GNPX) Stock Falls 0.4% – Here’s Why

Genprex (NASDAQ:GNPX) fell 0.4% during trading on Monday. The stock traded as low as $2.16 and last traded at $2.23. Approximately 241,574 shares changed hands during trading, an increase of 27% from the average session volume of 190,479 shares. The stock had previously closed at $2.24.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Genprex has a consensus rating of “Sell”.

Genprex Trading Down 0.4%

The firm’s 50-day simple moving average is $2.93 and its two-hundred day simple moving average is $20.55. The stock has a market capitalization of $1.83 million, a PE ratio of -0.02 and a beta of -0.99.

Genprex (NASDAQ:GNPX) last released its earnings results on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

Genprex Company Profile

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles.

Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.